A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Trial Profile

A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE-021
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Aug 2018 Planned End Date changed from 18 Oct 2019 to 18 Oct 2021.
    • 20 Aug 2018 Results evaluating efficacy and safety published in the Journal of Thoracic Oncology
    • 05 Jun 2018 Results of overall survival at 24 months from cohort G (n=123) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top